Patents Assigned to Asuragen, Inc.
-
Publication number: 20140350086Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: August 13, 2014Publication date: November 27, 2014Applicant: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20140348908Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: August 13, 2014Publication date: November 27, 2014Applicant: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20140274791Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer.Type: ApplicationFiled: April 11, 2014Publication date: September 18, 2014Applicant: Asuragen, Inc.Inventors: Elizabeth Mambo, David Brown, Alex T. Adai, Tiffany Sanford, Stephanie Volz, Ashish Choudhary
-
Publication number: 20140248625Abstract: This disclosure relates to methods of determining the presence and position of AGG or interruptor elements within a trinucleotide (for example, CGG) repeat region, and to methods of determining the number of repeats present in this region, by amplifying a set of products with a set of primers of which at least one comprises a portion of the CGG repeat region, and resolving the products to produce a representation of product size and abundance.Type: ApplicationFiled: February 26, 2014Publication date: September 4, 2014Applicant: Asuragen, Inc.Inventors: Gary J. LATHAM, Liangjing CHEN, Sachin SAH
-
Publication number: 20140235469Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.Type: ApplicationFiled: October 28, 2013Publication date: August 21, 2014Applicant: ASURAGEN, INC.Inventors: Jeffrey SHELTON, Kevin KELNAR, Stephanie VOLZ, Alex ADAI, David BROWN
-
Publication number: 20140228228Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.Type: ApplicationFiled: October 24, 2013Publication date: August 14, 2014Applicant: ASURAGEN, INC.Inventors: David Brown, Rick Conrad, Eric Devroe, Marianna Goldrick, Kerri Keiger, Emmanuel Labourier, Ivonne Moon, Patricia Powers, Jeffrey Shelton, Jaclyn Shingara
-
Patent number: 8765709Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: August 28, 2013Date of Patent: July 1, 2014Assignee: Asuragen, Inc.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Patent number: 8735074Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer.Type: GrantFiled: August 27, 2010Date of Patent: May 27, 2014Assignee: Asuragen, Inc.Inventors: Elizabeth Mambo, David Brown, Alex T. Adai, Tiffany Sanford, Stephanie Volz, Ashish Choudhary
-
Publication number: 20140141423Abstract: The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain aspects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.Type: ApplicationFiled: October 10, 2013Publication date: May 22, 2014Applicant: ASURAGEN, INC.Inventors: Sylvie Beaudenon, Laura Elizondo, Martina Doleshal, David Brown, Emmanuel Labourier
-
Publication number: 20140100124Abstract: Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient.Type: ApplicationFiled: March 13, 2013Publication date: April 10, 2014Applicant: Asuragen, Inc.Inventor: Asuragen, Inc.
-
Patent number: 8679757Abstract: This disclosure relates to methods of determining the presence and position of AGG or interruptor elements within a trinucleotide (for example, CGG) repeat region, and to methods of determining the number of repeats present in this region, by amplifying a set of products with a set of primers of which at least one comprises a portion of the CGG repeat region, and resolving the products to produce a representation of product size and abundance.Type: GrantFiled: February 16, 2010Date of Patent: March 25, 2014Assignee: Asuragen, Inc.Inventors: Gary J. Latham, Liangjing Chen, Sachin Sah
-
Publication number: 20140031415Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: August 28, 2013Publication date: January 30, 2014Applicant: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20140024035Abstract: Disclosed herein are methods for the automated reconstruction of a genotype of a gene, fragment, or genomic region using exhaustive enumeration. The methods can be used to reconstruct the genotype of any GC-rich sequence, such as the CGG repeat region in the 5? UTR of FMR1 or the CCG repeat region in the 5? UTR of FMR2. Also disclosed is an apparatus for use in conducting automated genotype reconstruction, as well as methods of diagnosis and treatment using exhaustive enumeration methods to reconstruct and identify genotypes associated with a disease or disorder.Type: ApplicationFiled: July 19, 2013Publication date: January 23, 2014Applicant: ASURAGEN, INCInventors: Ashish Choudhary, Gary Latham, Sachin Sah
-
Patent number: 8597892Abstract: This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.Type: GrantFiled: May 21, 2010Date of Patent: December 3, 2013Assignee: Asuragen, Inc.Inventors: Jeffrey Shelton, Kevin Kelnar, Stephanie Volz, Alex Adai, David Brown
-
Patent number: 8568971Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.Type: GrantFiled: September 24, 2010Date of Patent: October 29, 2013Assignee: Asuragen, Inc.Inventors: David Brown, Rick Conrad, Eric Devroe, Marianna Goldrick, Kerri Keiger, Emmanuel Labourier, Ivonne Moon, Patricia Powers, Jeffrey Shelton, Jaclyn Shingara
-
Patent number: 8563708Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: August 10, 2007Date of Patent: October 22, 2013Assignee: Asuragen, Inc.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20130184175Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient.Type: ApplicationFiled: January 7, 2013Publication date: July 18, 2013Applicant: Asuragen, Inc.Inventor: Asuragen, Inc.
-
Publication number: 20130157884Abstract: Embodiments concern methods and compositions for evaluating a pancreatic cyst in a patient based on the expression levels of one or more miRNAs to determine whether the pancreatic cyst is a low or high risk lesion and in further need of treatment such as resection.Type: ApplicationFiled: October 26, 2012Publication date: June 20, 2013Applicant: Asuragen, Inc.Inventor: Asuragen, Inc.
-
Patent number: 8465914Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.Type: GrantFiled: July 2, 2012Date of Patent: June 18, 2013Assignee: Asuragen, Inc.Inventors: David Brown, Rick Conrad, Eric Devroe, Marianna Goldrick, Kerri Keiger, Emmanuel Labourier, Ivonne Moon, Patricia Powers, Jeffrey Shelton, Jaclyn Shingara
-
Publication number: 20130143945Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: February 7, 2013Publication date: June 6, 2013Applicant: ASURAGEN, INC.Inventor: Asuragen, Inc.